IMUX vs ARQT vs VNDA vs IQV vs PTCT

For growth investors, PTC Therapeutics, Inc.

(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 9. 6x trailing P/E (115. 7x forward), making it the more compelling value choice. Analysts rate Immunic, Inc. (IMUX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 9. 6x versus IQVIA Holdings Inc. at 23. 1x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, PTC Therapeutics, Inc.

(PTCT) delivered a total return of +73. 9%, compared to -90. 8% for Immunic, Inc. (IMUX). Over 10 years, the gap is even starker: PTCT returned +995. 3% versus IMUX's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), PTC Therapeutics, Inc.

(PTCT) is the lower-risk stock at 0. 89β versus Immunic, Inc. 's 1. 80β — meaning IMUX is approximately 102% more volatile than PTCT relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PTC Therapeutics, Inc.

(PTCT) is pulling ahead at 114. 5% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -102. 0% for Vanda Pharmaceuticals Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -70. 0% for VNDA. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 2x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 108. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VNDA: 133. 6% to $14. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89), +995. 3% 10Y return). Immunic, Inc. (IMUX) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +995. 3%, IMUX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMUX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; VNDA is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; PTCT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.